

Table of Contents – Overview

Preface	V
Contributors to the Sixth Edition	IX
Table of Contents – Detailed	XV
 1 Patentable Subject Matter/Industrial Applicability/Utility: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	 1
1.1 Patentable Subject Matter/Industrial Applicability: EPO (Articles 52 and 53 EPC1973, Articles 52, 53 and 54[5] EPC2000, the EU Directive 98/44/EC of July 6, 1998 and its Implementation by the EPO)	1
1.2 Patentable Subject Matter/Utility: US (35 U.S.C. § 101 (1984))	16
1.3 Patentable Subject Matter/Industrial Applicability: JPO	36
 2 Patentable Subject Matter: The EPO's Case Law	 43
 3 The Person Skilled in the Art: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	 100
3.1 The Person Skilled in the Art: EPO	100
3.2 The Person Skilled in the Art: US	101
3.3 The Person Skilled in the Art: JPO	104
 4 The Person Skilled in the Art: The EPO's Case Law	 106
 5 Corrections and Amendments: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	 110
5.1 Corrections and Amendments: EPO (Article 123 and Rule 88 EPC1973/Rule 139 EPC2000)	110
5.2 Corrections and Amendments: US	118
5.3 Corrections and Amendments: JPO	125
 6 Corrections and Amendments: The EPO's Case Law	 131
 7 Clarity of Claims: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	 251
7.1 Clarity of Claims: EPO (Article 84 EPC)	251
7.2 Clarity of Claims: US	254
7.3 Clarity of Claims: JPO	259
 8 Clarity of Claims: The EPO's Case Law	 262
 9 Enabling Disclosure: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	 313
9.1 Enabling Disclosure: EPO (Article 83 EPC)	313
9.2 Enabling Disclosure: US	324
9.3 Enabling Disclosure: JPO	342

Table of Contents – Overview

10	Enabling Disclosure: The EPO's Case Law	350
11	Deposit: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	523
11.1	Deposit: EPO (Article 83 EPC and Rule 28 and Rule 28a EPC1973/Rules 31 to 34 EPC2000 of the Implementing Regulations)	523
11.2	Deposit: US	530
11.3	Deposit: JPO	533
12	Deposit: The EPO's Case Law	535
13	Priority: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	545
13.1	Priority: EPO (Articles 87 to 89 EPC)	545
13.2	Priority: US	551
13.3	Priority: JPO	564
14	Priority: The EPO's Case Law	567
15	Novelty: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	613
15.1	Novelty: EPO (Article 54 EPC/Article 54 EPC2000)	613
15.2	Novelty: US	631
15.3	Novelty: JPO	646
16	Novelty: The EPO's Case Law	654
17	Inventive Step: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	831
17.1	Inventive Step: EPO (Article 56 EPC)	831
17.2	Inventive Step: US	845
17.3	Inventive Step: JPO	869
18	Inventive Step: The EPO's Case Law	879
19	Decisions of the EPO Dealing with Procedural Issues and Procedural Changes Due to EPC2000	1264
20	Drafting Claims for a European Patent Application	1357
21	Examples of Claims for a US Patent Application	1359
22	Examples of Claims for a Japanese Patent Application	1373
23	How to Draft and File a European Patent Application	1383
24	How to Draft the Description of a US Patent Application	1395
25	How to Draft the Description of a Japanese Patent Application	1417

26	How to Keep Notebooks for Successful Interferences	1423
27	Extensions to Patent Term	1428
28	AIA Post-Grant Proceedings in the United States	1438
	Decisions of the EPO	1459
	Decisions on U.S. Cases	1503
	Decisions on Japanese Cases	1526
	European Statutes	1529
	Cross-Reference List Article EPC1973 Article/Rule EPC2000	1530
	Cross-Reference List Rule EPC1973 Rule EPC2000	1532
	U.S. Statutes	1537
	Japanese Statutes	1538
	Index	1539

Table of Contents – Detailed

Preface	V
Contributors to the Sixth Edition	IX
Table of Contents – Overview	XI
1 Patentable Subject Matter/Industrial Applicability/Utility: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	1
1.1 Patentable Subject Matter/Industrial Applicability: EPO (Articles 52 and 53 EPC1973, Articles 52, 53 and 54[5] EPC2000, the EU Directive 98/44/EC of July 6, 1998 and its Implementation by the EPO)	1
1.2 Patentable Subject Matter/Utility: US (35 U.S.C. § 101 (1984))	16
1.3 Patentable Subject Matter/Industrial Applicability: JPO	36
2 Patentable Subject Matter: The EPO's Case Law	43
2.1 The Exclusion of »Essentially Biological Processes for the production of Plants or Animals«: Article 53(b) EPC2000	43
2.2 The Exclusion of Plant and Animal Varieties from Patent Protection in Consideration of Article 53 EPC	48
2.3 To What Extent Are Embryonic Stem Cells Patentable: Rule 28(c) EPC2000/Rule 23d(c) EPC1973	63
2.4 The patenting of human DNA is not intrinsically ethical	76
2.5 Compounds and Discoveries, Industrial Applicability	78
2.6 The Patenting of Pharmaceutical Inventions	90
2.7 The Patenting of Diagnostic Inventions and Screening Methods	98
3 The Person Skilled in the Art: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	100
3.1 The Person Skilled in the Art: EPO	100
3.2 The Person Skilled in the Art: US	101
3.3 The Person Skilled in the Art: JPO	104
4 The Person Skilled in the Art: The EPO's Case Law	106
5 Corrections and Amendments: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	110
5.1 Corrections and Amendments: EPO (Article 123 and Rule 88 EPC1973/Rule 139 EPC2000)	110
5.2 Corrections and Amendments: US	118
5.3 Corrections and Amendments: JPO	125
6 Corrections and Amendments: The EPO's Case Law	131
6.1 T 184/91, »Glu-Gln/CELTRIX«, EP-A 169 016, G 11/91, »Glu-Gln/CELTRIX«, EP-A 169 016; and T 1147/98, »Cartilage-inducing factor/CELTRIX PHARMACEUTICALS INC.«, EP-B1 169 016	131
6.2 T 161/86, »Amino acid sequence modification/ELI LILLY«, EP-A 10 421	132
6.3 T 552/91, »Chroman derivatives/MERCK«, EP-A 273 262	133

Table of Contents – Detailed

6.4	T 21/86, »Amendments/AMERICAN MONITOR CORP.«, EP-A 9 222	134
6.5	T 365/88 »Improved vectors/BIOGEN«, EP-A 41 767	135
6.6	T 449/90, »Treatment of plasma/CEDARS-SINAL«, EP-B 94 611	135
6.7	T 157/90, »Human calcitonin structural gene/CELL-TECH«, EP-A 70 675 . .	136
6.8	T 923/92, »t-PA/GENENTECH«, EP-B1 93 619, OJ EPO 1996, 564	137
6.9	T 749/94, »Erythropoietin/GENETICS INSTITUTE«, EP-B1 209 539	140
6.10	T 379/95, »Hormones/ARS«, EP-B1 160 699	141
6.11	T 1046/96, »Pertussis/LELAND STANFORD«, EP-B1 275 689	142
6.12	T 277/95, »Production of erythropoietin/GENETICS INSTITUTE«, EP-B1 411 678	142
6.13	T 656/94, »Colony-stimulating factor/KIRIN-AMGEN«, EP-B1 237 545 . . .	143
6.14	T 824/94, »LAV/INSTITUT PASTEUR«, EP-B1 178 978	144
6.15	T 138/95, »Intrapulmonary delivery/GENENTECH INC.«, EP-B1 257 956 .	145
6.16	T 985/95, »Treatment of infertility/NOVO NORDISK A/S«, EP-B1 300 021	145
6.17	T 289/97, »Brassica/CALGENE«, EP-B1 270 615	146
6.18	T 354/97, »Protein secretion/GENENTECH«, EP-B1 88 632	147
6.19	T 658/98, »Interferon-beta 2A/YEDA RESEARCH«, EP-A 645 542	148
6.20	T 588/95, »Chimera monoclonal antibody/RESEARCH DEVELOPMENT«, EP-B1 171 496	148
6.21	T 188/97, »NANBV/Chiron Corporation«, EP-B1 318 216	149
6.22	T 1054/97, »Insect control/AVENTIS«, EP-B1 451 878	150
6.23	T 32/97, »Deleted tk-PRV vaccines/NOVAGENE«, EP-B1 149 040	151
6.24	T 339/98, »Vitamin K-dependent proteins/ELI LILLY«, EP-B1 363 126	151
6.25	T 725/99, »Live vaccines/LELAND STANFORD JUNIOR UNIVERSITY«, EP-B1 184 086	152
6.26	T 351/98, »HIV-1/CHIRON CORPORATION«, EP-B1 181 150	153
6.27	T 239/95, »Herpes simplex viral proteins/AMERICAN CYANAMID CO.«, EP-B1 101 655	154
6.28	T 450/98, »BPI fragments/NEW YORK UNIVERSITY«, EP-B1 375 724 . . .	154
6.29	T 93/98, »TNF inhibiting protein/BASF«, EP-B1 471 701	154
6.30	T 1118/98, »Nucleic acids/DU PONT DE NEMOURS«, EP-B1 520 039 . . .	155
6.31	T 160/99, »Chlamydia/WASHINGTON«, EP-B1 264 434	156
6.32	T 232/99, »Protein production/ALUSUISSE HOLDINGS A.G.«, EP-B1 239 292	156
6.33	T 756/00, »Immunotherapy/CENTOCOR INC.«, EP-A 755 683	157
6.34	T 346/01, »Osteoporosis/NOVARTIS«, EP-A 560 723	157
6.35	T 216/96, »Process for amplifying, detecting and/or cloning nucleic acid sequences/F. HOFFMANN-LA ROCHE AG«, EP-B1 200 362	157
6.36	T 785/97, »Support-bound oligonucleotides/OXFORD GENE TECHNOLOGY LIMITED«, EP-B1 386 229	158
6.37	T 310/99, »Down Syndrome/MACRI«, EP-B1 409 956	158
6.38	T 944/99, »Pesticidal toxins/MYCOGEN CORPORATION«, EP-B1 340 948	159
6.39	T 279/00, »Asymmetric reduction process/AVECIA LTD.«, EP-B1 658 211 . .	160
6.40	T 502/00, »Determination of an analyte/DADE«, EP-B1 492 499	160
6.41	T 608/00, »Transgenic bovine/PHARMING«, EP-B1 502 976	160
6.42	T 748/00, »Oligomer libraries/AFFYMAX«, EP-B1 604 552	160
6.43	T 1000/00, »Test device/ROCHE«, EP-B1 654 659	161
6.44	T 1228/01, »Zona pelucida antigens/ZONAGEN INC.«, EP-A 396 552	162
6.45	T 86/01, »Engineered bacteriophages/ACAMBIS«, EP-B1 552 267	164
6.46	T 98/01, »Allergenic proteins/IMMUNOLOGIC PHARMACEUTICAL CORPORATION«, EP-B1 463 059	164
6.47	T 189/01, »IFN-2/IL-6R/YEDA RESEARCH AND DEVELOPMENT CO., LTD.«, EP-B1 413 908	164

6.48	T 1133/00, »Tumor suppression/UNIVERSITY OF CALIFORNIA«, EP-B1 475 623	165
6.49	T 286/01, »Humanised antibodies/CELLTECH THERAPEUTICS LTD.«, EP-B1 460 167	165
6.50	T 345/01, »Cellulose degrading enzyme/NOVOZYMES«, EP-B1 531 315	166
6.51	T 836/01, »Interferon-beta2/YEDA RESEARCH AND DEVELOPMENT CO. LTD.«, EP-A 835 661	166
6.52	T 882/01, »Protein expression system/CELLTECH«, EP-B1 651 803	166
6.53	T 1014/01, »Recombinant immunoconjugates/BRISTOL-MYERS SQUIBB CO.«, EP-B1 439 095	167
6.54	T 1100/01, »Truncated transmembrane PACE/GENETICS«, EP-B1 574 402	167
6.55	T 1080/01, »Thermostable enzyme/F. HOFFMANN-LA ROCHE«, EP-B1 258 017	168
6.56	T 161/02, »Transgenic Zea mays plants/SYNGENTA«, EP-B1 513 849	169
6.57	T 579/01, »Cytoplasmic male sterile plants/ENZA ZADEN«, EP-B1 771 523	169
6.58	T 960/02, »Transfection/TRANSKARYOTIC THERAPIES«, EP-B1 649 464	170
6.59	T 1067/02, »Changed epitopes/NOVOZYMES«, EP-B1 561 907	171
6.60	T 157/03, »Reducing blood loss/ZYMOGENETICS«, EP-B1 624 095	172
6.61	T 1050/99, »Carbonyl hydrolases/GENENCOR«, EP-B1 251 446	172
6.62	T 931/01, »Ribozyme/UNIVERSITY PATENTS«, EP-B1 291 533	173
6.63	T 877/03, »Anti-CD30 antibodies/ROCHE«, EP-B1 805 871	174
6.64	T 626/00, »Framework-mutated antibodies/WELLCOME«, EP-B1 549 581	174
6.65	T 27/04, »Japanese hepatitis C virus/CHIRON«, EP-B1 419 182	175
6.66	T 20/04, »Flt3 ligands/SCHERING«, EP-B1 699 236	176
6.67	T 1331/04, »MSF/GENETICS INSTITUTE«, EP-A 567 599	177
6.68	T 342/02 and T 462/07, »End-labeled nucleotide probe/ENZO«, EP-B1 330 221,	177
6.69	T 464/94, »Transformation of plant genetic material/NOVARTIS«, EP-B1 164 575	178
6.70	T 506/02, »Measles virus/IMPFINSTITUT«, EP-B1 780 475	178
6.71	T 1052/02, »Immunochromatographic method/PACIFIC BIOTECH«, EP-B1 466 914	178
6.72	T 937/02, »G-CSF/OSAKA BIOSCIENCE«, EP-A1 521 156	179
6.73	T 1189/02, »Homologous recombination/CELL GENESYS«, EP-B1 747 485	179
6.74	T 243/03, »Plant pathogens/MOGEN«, EP-B1 474 857	181
6.75	T 494/03, »Transgenic wheat/SYNGENTA«, EP-B1 674 715	181
6.76	T 79/04, »Prion proteins/PROTEUS«, EP-B1 616 613	181
6.77	T 94/04, »Cytokine antagonists/REGENERON«, EP-B1 726 954	182
6.78	T 168/04, »Yeast vector/YOCUM«, EP-B1 707 068	182
6.79	T 329/04, »Absorption of minerals/NESTLE«, EP-B1 1 003 532	183
6.80	T 491/04, »anti TNF- α antibody/PHARMACIA & UPJOHN«, EP-B1 492 448	183
6.81	T 500/01, »Humanized immunoglobulins/PROTEIN DESIGN LABS, INC.«, EP-B1 451 216	184
6.82	T 21/05, »CTL responses to HCV/SCRIPPS«, EP-B1 759 937	185
6.83	T 35/05, »TNF ligands/YEDA«, EP-B1 585 939	186
6.84	T 59/05, »Galactopyranosides/PROCUR«, EP-A1 873 414	187
6.85	T 248/05, »Particulate direct label/INVERNESS«, EP-B1 560 411	187
6.86	T 313/05, »Apparatus for monitoring a polymerase chain reaction/APPLERA«, EP-B1 872 562	188
6.87	T 634/05, »Factor VIII:C/NOVARTIS«, EP-B1 466 199	189
6.88	T 1470/05, »HCV T-cell epitopes/INNOGENETICS«, EP-B1 725 824	190
6.89	T 1491/05, »Gene expression/CSIRO«, EP-A1 1 071 762	190
6.90	T 1181/06, »Polyketides/STANFORD«, EP-B1 725 778	191

Table of Contents – Detailed

6.91	T 25/06, «Botulinum toxin/SOLSTICE NEUROSCIENCES», EP-B1 1 112 082	191
6.92	T 1188/06, «Molecular evolution/BIOINVENT», EP-B1 988 378	192
6.93	T 1497/06, «GPCR/ARENA», EP-A1 1 580 271	192
6.94	T 1213/05, «Breast and ovarian cancer/UNIVERSITY OF UTAH», EP-B1 705 902	193
6.95	T 1048/05, «Luciferase/PERKIN ELMER LAS», EP-B1 610 937	195
6.96	T 582/06, «DNA mutagenesis/MAXYGEN», EP-B1 752 008	195
6.97	T 1099/06, «Transgenic plant cells/MAX PLANCK», EP-B1 290 799	196
6.98	T 411/02, «CTLA4 receptor/BRISTOL-MYERS SQUIBB», EP-B1 606 217	197
6.99	T 580/05, «Humanised antibodies/CELLTECH», EP-B1 626 390	197
6.100	T 542/04, «Soybean products/E.I. Du PONT DE NEMOURS», EP-B1 608359	198
6.101	T 1443/04, «Regeneration of Gramineae plants/SYNGENTA», EP-B1 332 581	199
6.102	T 725/05, «Humanized Immunoglobulins II/PDL», EP-B1 682 040	199
6.103	T 795/06, «Botulinum neurotoxine/MERZ», EP-B1 1 185 291	200
6.104	T 329/06, «Perfused microtissue/MIT», EP-B1 1 064 353	200
6.105	T 405/06, «Immunoglobulins/BRUSSEL», EP-B1 656 946	201
6.106	T 801/06, «Cancer treatment with HSV mutant/CRUSADE», EP-B1 773 785	201
6.107	T 997/06, «Insulin preparation/NOVO NORDISK», EP-B1 921 812	202
6.108	T 1107/06, «Botulinum toxins/ALLERGAN», EP-B1 1 005 867	202
6.109	T 1408/06, «VEGF-related protein/GENENTECH», EP-B1 848 755	203
6.110	T 1772/06, «Clarithromycin/ABBOTT», EP-B1 915 899	204
6.111	T 1790/06, «Expression of a gene/ALNYLAM» (December 9, 2008), EP-B1 1 144 623	204
6.112	T 382/07, «Ethereic oils/D&W TRADING», EP-B1 828 502	205
6.113	T 391/07, «Immunotherapy of cancer/UNIVERSITY OF PENNSYLVANIA», EP-B1 790 835	205
6.114	T 1898/07, «Interferon Formulations/BIOGEN», EP-B1 948 358	206
6.115	T 617/07, «Monoclonal NGF-antagonist antibodies/LAY LINE», EP-B1 1 181 318	207
6.116	T 665/07, «Heterologous genes/EDINBURGH», EP-B1 695 361	208
6.117	T 762/07, «Estrogen receptor/ORGANON», EP-B1 798 378	208
6.118	T 837/07, «Diagnostic primers/INFECTIO», EP-B1 804 616	209
6.119	T 1068/07, «Enzymatic DNA/SCRIPPS», EP-A1 981 646	209
6.120	T 1128/07, «HIV-2 variants/QUILAGEN», EP-B1 655 501	211
6.121	T 1331/07, «Collagen-like polymers/PROTEIN POLYMER», EP-B1 670 848	211
6.122	T 1437/07, «Botulinum toxin for treating smooth muscle spasm/ALLERGAN», EP-B1 1 010 431	212
6.123	T 1885/07, «Alphavirus vectors/BIOPTION», EP-B1 753 053	212
6.124	T 1/08, «Alphaviruses/BIOPTION», EP-B1 561 890	213
6.125	T 692/08, «Lawsonia intracellularis/BOEHRINGER», EP-B1 843 818	213
6.126	T 1022/08, «Trifunctional reagent/MITRA», EP-A1 1 569 690	214
6.127	T 1477/08, «ACE inhibitors/SANOFI-AVENTIS», EP-B1 1 212 081	214
6.128	T 2351/08, «Hsp70 protein/MULTHOFF», EP-B1 1 066 050: Recording of Oral Proceedings by a Party	214
6.129	T 1001/07, «Ointment/KAPAJ», EP-A1 1 532 982	215
6.130	T 1644/08, «Endoglucanases/NOVOZYMES», EP-B1 815 209	215
6.131	T 445/09, «Treatment of autoimmune diseases/GENENTECH», EP-B1 1 176 981	216
6.132	T 783/09, «Antidiabetic combinations/NOVARTIS», EP-B1 1 248 604	216
6.133	T 878/09, «Method for the detection of prion proteins/PROTHERICS», EP-B1 616 613	217
6.134	T 1271/09, «Expression of a gene/ALNYLAM», EP-B1 1 214 945	217

6.135	T 244/10, »Diagnosis autoimmune/DIAGNOSTIC HYBRIDS«, EP-A1 1 268 846	218
6.136	T 305/07, »Trisulfides/PFIZER«, EP-B1 1 095 055	218
6.137	T 1456/06, »Telomerase/GERON«, EP-B1 841 396	219
6.138	T 1172/08, »Method for determining T-cell epitopes/GENENCOR«, EP-B1 1 073 754	219
6.139	T 76/09, »Protein fragment complementation assay/ODYSSEY«, EP-A1 1 305 627	220
6.140	T 341/09, »Antibody/WELLCOME«, EP-B1 1 247 865;	221
6.141	T 583/09, »Novel genes/MILLENIUM«, EP-A1 1 194 534	221
6.142	T 1803/09, »Markers congestive heart failure/SYN.X PHARMA«, EP-A1 1 423 705	222
6.143	T 191/08, »Haemagglutinin molecule complex/NOVARTIS«, EP-B1 589 348	223
6.144	T 1919/11, »Production of taxanes/BIOTECH«, EP-A1 1 398 384	223
6.145	T 1205/07, »Adenoviral packaging system/CRUCELL«, EP-B1 833 934	224
6.146	T 1572/07, »TEM17/THE JOHNS HOPKINS UNIVERSITY«, EP-A1 1 307 557	225
6.147	T 611/08, »Botulinum toxins/ALLERGAN INC.«, EP-B1 1 103 267	225
6.148	T 713/08, »Neurotrophins/H. LUNDBECK A/S«, EP-A1 1 589 988	226
6.149	T 824/08, »Non-segmented negative strand RNA viruses/CRUCELL«, EP-B1 846 181	227
6.150	T 1309/08, »Exendins/AMYLIN PHARMACEUTICALS, INC.«, EP-B1 1 246 638	227
6.151	T 1582/08, »Collagen/INTEGRA LIFESCIENCES CORP.«, EP-B1 1 017 415	228
6.152	T 1715/08, »Fucosyltransferase/ALTMANN«, EP-B1 1 151 109	228
6.153	T 1925/08, »Infrared dye/SIEMENS«, EP-B1 1 111 386	229
6.154	T 2003/08, »Dilated cardiomyopathy/EDWARDS«, EP-B1 862 444	229
6.155	T 2126/08, »Surface antigen/ORTHO-CLINICAL DIAGNOSTICS«, EP-A1 1 114 906	230
6.156	T 250/09, »Separation of nucleic acid mixtures/QUIAGEN GmbH«, EP-B1 1 146 049	231
6.157	T 591/09, »c-Fos Induced Growth Factor/VEGENICS«, EP-B1 853 668	231
6.158	T 1042/09, »Bioarray chip/AFFYMETRIX«, EP-B1 764 214	231
6.159	T 1263/09, »Coupled PCR/CORNELL«, EP-A1 1 736 554	232
6.160	T 1509/09, »High density oligonucleotide arrays/AFFYMETRIX«, EP-B1 853 679	234
6.161	T 2471/09, »Aminoacyl-tRNA Synthetase/SCRIPPS«, EP-A1 1 456 360	234
6.162	T 2384/09, »Treatment of connective tissue/NUTRAMAX«, EP-A1 1 762 247	234
6.163	T 1592/10, »Detection of Candida Protease/KIMBERLY-CLARK«, EP-A1 1 960 784	235
6.164	T 610/06, »hPTH 1-34/ELI LILLY«, EP-B1 1 059 933	235
6.165	T 103/09, »Stable liquid human EPO at room temperature/ F. Hoffmann-La Roche AG«, EP-B1 1 311 285	235
6.166	T 1074/09, »Vaccine/SANOFI PASTEUR LIMITED«, EP-B1 1 200 122	236
6.167	T 1813/09, »Dm-resistance markers/ENZA ZADEN BEHEER«, EP-B1 1 179 089	237
6.168	T 1912/09, »Methods for detection of virus/ADVANCED LIFE SCIENCE«, EP-B1 967 484	238
6.169	T 1980/09, »Multi-analyte immunoassay/RANDOX«, EP-B1 1 203 957	239
6.170	T 137/10, »Human growth hormone/CSL, LTD; MONASH UNIV.«, EP-B1 889 733	239
6.171	T 665/10, »Marking with DNA/TRACETAG«, EP-B1 1 171 633	241
6.172	T 1039/10, »Copolymers/HARVARD COLLEGE«, EP-A1 1 438 061	241

Table of Contents – Detailed

6.173	T 1771/10, »Amendments – intermediate generalisation/BAYER HEALTH-CARE«, EP-A1 1 743 038	241
6.174	T 1822/10, »Nucleic acid concentration/MEDICAL« (July 3, 2014), EP-B1 1 482 036	242
6.175	T 1866/10, »Fluorescent PCR sequencing/LIFE TECHNOLOGIES«, EP-B1 1 368 460	242
6.176	T 2134/10, »S. Pneumonia antigen/HUMAN GENOME SCIENCES«, EP-B1 942 983	243
6.177	T 2350/10, »Quantification of Botulinum Toxin/IPSEN«, EP-B1 1 597 584	244
6.178	T 1648/11, »Chromosome specific staining/UNIVERSITY OF CALIFORNIA«, EP-B1 885 971	245
6.179	T 494/09, »Solution de facteur VIII sécurisée viralement/LABORATOIRE FRANÇAIS«, EP-B1 1 037 923	245
6.180	T 197/09, »Récepteur de l'IL-13/SANOFI«, EP-B1 876 482	247
6.181	T 730/10, »Assay/BECKMAN COULTER«, EP-B1 758 401	248
6.182	T 1094/10, »Double stranded RNA modified 2'O-Methyl aligned phase shift pattern/SILENCE THERAPEUTICS«, EP-B1 1 527 176	249
6.183	T 715/10, »Stable liquid exendin formulations/AMYLIN PHARMACEUTICALS«, EP-B1 1 140 145	250
7	Clarity of Claims: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	251
7.1	Clarity of Claims: EPO (Article 84 EPC)	251
7.2	Clarity of Claims: US	254
7.3	Clarity of Claims: JPO	259
8	Clarity of Claims: The EPO's Case Law	262
8.1	T 301/87, »Alpha-interferons/BIOGEN«, EP-B 32 134, OJ EPO 1990, 335 to 358	262
8.2	T 281/86, »Preprothauatin/UNILEVER«, EP-A 54 331, OJ EPO 1989, 202 to 209	263
8.3	T 181/87, »DNA transfer vector/THE REGENTS OF THE UNIVERSITY OF CALIFORNIA«, EP-A 20 251	264
8.4	T 269/87, »Prochymosin/CELLTECH«, EP-A 68 691	265
8.5	T 347/87, »Method of constructing a replicable cloning vehicle/GENENTECH«, EP-A 22 242	265
8.6	T 130/90 »Recombinant Monoclonal Antibody/UNIVERSITY OF TEXAS SYSTEM«, EP-B 68 763	266
8.7	T 391/91, »Ice nucleating/UNIVERSITY OF CALIFORNIA«, EP-A 112 342	267
8.8	T 430/92, »Growth of tulips/SUMITOMO«, EP-B1 188 933	268
8.9	T 749/94, »Erythropoietin/GENETICS INSTITUTE«, EP-B1 209 539	269
8.10	T 464/94, »Transformation of plant genetic material/NOVARTIS«, EP-B1 164 575	269
8.11	T 250/96, »Transformation/NOVARTIS«, EP-A1 429 093	270
8.12	T 277/95, »Production of erythropoietin/GENETICS INSTITUTE«, EP-B1 411 678	271
8.13	T 484/98, »Modified yeast/ELSWORTH«, EP-A 463 024	272
8.14	T 965/98, »DNA amplification/HOFFMANN-LA ROCHE«, EP-A 509 612	272
8.15	T 966/98, »DNA detection/HOFFMANN-LA ROCHE«, EP-A 502 589	273
8.16	T 188/97, »NANBV/Chiron Corporation«, EP-B1 318 216	273
8.17	»Serotonin receptor/ELI LILLY«, EP-A 449 562, OJ EPO 2001, 103	273

8.18	T 1044/99, »Ionophore antibiotics/UNGDA«, EP- 615 544	274
8.19	T 680/98, »Improved vectors II/BIOGEN«, EP-B1 41 767	274
8.20	T 822/98, »Probes/BIO-RAD«, EP-B1 246 864	275
8.21	T 239/95, »Herpes simplex viral proteins/AMERICAN CYANAMID CO.«, EP-B1 101 655	276
8.22	T 64/00, »Insecticidal plant expression/MYCOGEN«, EP-B1 359 472	276
8.23	T 984/00, »Ti-plasmid vectors/MAX-PLANCK-GESELLSCHAFT«, EP-A 290 799	278
8.24	T 1084/00, »HIV-3 variants/INNOGENETICS«, EP-A1 657 532	278
8.25	T 397/02, »Endogenous gene expression/APPLIED RESEARCH SYS«, EP-B 505 500	279
8.26	T 285/01, »Bone resorption/WASHINGTON RESEARCH FOUNDATION«, EP-B1 394 296	279
8.27	T 610/01, »Plant growth/LONG ASHTON RESEARCH STATION«, EP-A 703 983	280
8.28	T 347/02, »Neoplastic phenotype/UNIVERSITY OF CALIFORNIA«, EP-B1 440 744	280
8.29	T 1074/00, »Hematopoietic growth factors/GENETICS INSTITUTE«, EP-B1 314 705	281
8.30	T 378/02, »Analysis of polynucleotide sequences/OXFORD GENE TECHNOLOGY«, EP-B1 373 203	282
8.31	T 1146/02, »Vaccines containing a saponin and a sterol/SMITHKLINE BEECHAM«, EP-B1 822 831	283
8.32	T 741/03, »Treatment of diabetes/LONDON HEALTH SCIENCES«, EP-B1 762 890	283
8.33	T 748/04, »Bioactive factors of aloe vera plants/CARRINGTON«, EP-A1 871 460	284
8.34	T 843/04, »Gas driven fermentation/PRAXAIR«, EP-B1 829 534	284
8.35	T 1326/04, »Avian adenovirus vector/COMMON-WEALTH CSIRO«, EP-A1 690 612	285
8.36	T 29/05, »PVA/BRISTOL-MYERS«, EP-A1 718 402	286
8.37	T 710/05, »NMDA oxidizing agents/THE CHILDREN'S MEDICAL CEN- TER«, EP-A1 486 621	287
8.38	T 723/05, »Growth hormone/PHARMACIA AKTIEBO-LAG«, EP-B1 587 858	287
8.39	T 1060/05, »Security system/CRIME SOLUTIONS«, EP-A1 1 230 392	288
8.40	T 1300/05, »RET screening assay/PROGENICS«, EP-A1 847 452	288
8.41	T 25/06, »Botulinum toxin/SOLSTICE NEUROSCIEN-CES«, EP-B1 1 112 082	289
8.42	T 18/02, »Mutant alpha-amylase/GENENCOR«, EP-B1 689 589	289
8.43	T 412/06, »Proteinase inhibitor/MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG«, EP-A1 1 207 876	290
8.44	T 1018/06, »Ischemia detection/ISCHEMIA«, EP-A1 1 411 356	291
8.45	T 1599/06, »Mycobacterium vaccinating agent/UNIVERSITY OF CALIFORNIA«, EP-B1 771 322	291
8.46	T 411/02, »CTLA4 receptor/BRISTOL-MYERS SQUIBB«, EP-B1 606 217	292
8.47	T 640/06, »HSV particles/BIOGEN«, EP-B1 1 135 408	292
8.48	T 936/06, »Bacteriophage preparations/NYMOX«, EP-A1 895 534	293
8.49	T 1815/06, »Pre-ligand association domain/THE GOVERNMENT OF THE UNITED STATES«, EP-A1 1 263 788	294
8.50	T 449/08, »Renal clearance/U.D. TESTING«, EP-A1 817 966	294
8.51	T 692/08, »Lawsonia intracellularis/BOEHRINGER«, EP-B1 843 818	295
8.52	T 744/08, »Recovery of virus/XENOVA«, EP-B1 1 002 055	295
8.53	T 1423/08, »Medium supplement/LIFE TECHNOLOGIES«, EP-986 635	295

Table of Contents – Detailed

8.54	T 1644/08, »Endoglucanases/NOVOZYMES«, EP-B1 815 209	296
8.55	T 878/09, »Method for the detection of prion proteins/PROTHERICS«, EP-B1 616 613	297
8.56	T 2278/09, »Analyte capture device/ABBOTT«, EP-A1 1 369 691	297
8.57	T 1859/08, »Anti-Erb2 antibodies/GENENTECH, INC.«, EP-A1 1 037 926	297
8.58	T 2181/08, »TREM-1 splice variant/GENEPRINT«, EP-A1 1 351 702	298
8.59	T 493/09, »Hepatitis C/MERCK SHARP & DOHME CORP.«, EP-B1 858 343	299
8.60	T 1398/09, »Amplification of DNA/THE SECRETARY OF STATE FOR DEFENCE«, EP-A1 1 109 934	300
8.61	T 2272/09, »L-threonine production/EVONIK DEGUSSA«, EP-A1 1 483 393	300
8.62	T 2311/09, »Eotaxin/IMPERIAL INNOVATIONS LTD.«, EP-B1 719 331	301
8.63	T 2101/09, »Human Delta3 – Notch/MILLENIUM«, EP-B1 972 041	301
8.64	T 18/10, »Caries lectin detection/UNIVERSITY SOUTHERN CALIFORNIA«, EP-A1 1 616 035	302
8.65	T 2195/09, »Korianderol/UNIVERSITÄTSKLINIKUM FREIBURG«, EP-A1 1 598 073	303
8.66	T 1048/10, »NaV1.8 specific zink finger proteins/SANGAMO BIOSCIENCES, INC.«, EP-A1 1 737 498	303
8.67	T 1587/10, »Controlling infections/EGENOMICS«, EP-A1 1 315 828	305
8.68	T 2106/10, »Tenascin binding to fibronectin/NOVARTIS FORSCHUNGSSTIFTUNG«, EP-A1 1 416 954	306
8.69	T 2184/10, »Beet necrotic yellow vein virus resistance RNA1 replicase/SES«, EP-B1 1 169 463	306
8.70	T 2362/10, »Hybrid corn seed/MONSANTO«, EP-A1 2 059 601	307
8.71	T 2394/10, »Producing L-amino acids/AJINOMOTO«, EP-B1 1 013 765	307
8.72	T 206/11, »Bak promoter/TANOX«, EP-A1 1 009 395	308
8.73	T 865/11, »Cancer therapy/MAUDSLEY«, EP-A1 939 645	309
8.74	T 1293/11, »Transgenic plant – signal transduction stress-related protein«, EP-A1 1 760 145	309
8.75	T 494/09, »Solution de facteur VIII sécurisée viralement/LABORATOIRE FRANÇAIS«, EP-B1 1 037 923	310
8.76	T 2200/11, »Silencing interference dsRNA clusterin inhibition cancer Alzheimer/BRITISH COLUMBIA«, EP-A1 1 532 249	310
8.77	T 818/12, »Transgenic plant – cell cycle stress related protein«, EP-A1 1 795 600	311
9	Enabling Disclosure: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	313
9.1	Enabling Disclosure: EPO (Article 83 EPC)	313
9.2	Enabling Disclosure: US	324
9.3	Enabling Disclosure: JPO	342
10	Enabling Disclosure: The EPO's Case Law	350
10.1	Decisions on enablement of nucleic acid and protein inventions	350
10.2	Decisions on enablement of antibody technology inventions	425
10.3	Decisions on enablement of plant inventions	457
10.4	Decisions on enablement of inventions concerning viruses and their epitopes	467
10.5	Decisions on enablement of inventions concerning microorganisms	488
10.6	Decisions on enablement of other inventions	504

11	Deposit: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	523
11.1	Deposit: EPO (Article 83 EPC and Rule 28 and Rule 28a EPC1973/Rules 31 to 34 EPC2000 of the Implementing Regulations)	523
11.2	Deposit: US	530
11.3	Deposit: JPO	533
12	Deposit: The EPO's Case Law	535
12.1	T 361/87, »Microorganisms/NABISCO«, EP-A 97 973	535
12.2	T 39/88, »Microorganisms/CPC«, EP-A 111 683	535
12.3	T 106/88, »Microorganisms/CPC«, EP-A 112 459; T 90/88, »Microorganism/MICROLIFE«, EP-A 76 953; T 239/87, »Microorganisms/NABISCO«, EP-A 98 533; T 142/93, »Antibiotics/AMERICAN CYANAMID«, EP-A 182 152	536
12.4	T 118/87, »Amylolytic enzymes/CPC«, EP-A 34 470	536
12.5	J 8/87, J 9/87, »Submitting culture deposit information/IDAHO«, EP-A 155 476	536
12.6	Examining Division, »Deposit number/ROCKEFELLER«, EP 86 90 2639.3	537
12.7	T 815/90, »Hepatitis-A virus/UNITED STATES OF AMERICA«, EP-A 196 316, G 2/93, »Sufficiency of disclosure/Culture deposit information«	537
12.8	T 886/91, »Hepatitis B virus/BIOPEN«, EP-B1 13 828	540
12.9	T 412/93, »Erythropoietin/AMGEN«, EP-B1 148 605	540
12.10	T 923/92, »t-PA/GENENTECH«, EP-B1 63 619	541
12.11	T 128/92, »Interleukin-2/AJINOMOTO«, EP-B1 0 091 539	541
12.12	T 227/97, »Protein Rib/LINDAHL«, EP-A 656 014	542
12.13	T 1147/01, »PRRS Vaccine/AKZO NOBEL N.V.«, EP-B1 610 250	542
12.14	T 328/04, »Humoral immunity/DARTMOUTH COLLEGE«, EP-B1 742 721	542
12.15	T 107/09, »CD40 counter receptor/BRISTOL-MYERS SQUIBB COMPANY«, EP-B1 555 880	543
13	Priority: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	545
13.1	Priority: EPO (Articles 87 to 89 EPC)	545
13.2	Priority: US	551
13.3	Priority: JPO	564
14	Priority: The EPO's Case Law	567
14.1	T 81/87, »Preprorennin/COLLABORATIVE«, EP-A 57 350, OJ EPO 1990, 250 to 259	567
14.2	T 269/87, »Prochymosin/CELLTECH«, EP-A 68 691	568
14.3	T 301/87, »Alpha-interferons/BIOPEN«, EP-B 32 134, OJ EPO 1990, 335 to 358	568
14.4	T 886/91, »Hepatitis B virus/BIOPEN«, EP-B1 13 828	568
14.5	T 296/93, »HBV antigen production/BIOPEN«, EP-B1 182 442, OJ EPO 1995, 627	569
14.6	T 65/92, »HTLV/HARVARD COLLEGE«, EP-A 151 579	570
14.7	T 207/94, »Fibroblast interferon/BIOPEN«, EP-B1 41 313	571
14.8	T 441/93, »Cloning in Kluyveromyces/GIST BROCADES«, EP-B1 96 430	572
14.9	T 413/94, »Human GM-CSF/IMMUNEX CORP.«, EP-B1 183 350	572
14.10	T 380/94, »Insect control/PGS«, EP-B1 193 259	573

Table of Contents – Detailed

14.11	T 277/95 »Production of erythropoietin/GENETICS INSTITUTE«, EP-B1 411 678	574
14.12	T 236/96, »Interleukin 1/DAINIPPON«, EP-B1 188 920	575
14.13	T 919/93, »Heat treated factor VIII/CEDARS-SINAI«, EP-B1 94 611	576
14.14	T 51/95, »Mature leukocyte interferons/HOFFMANN-LA ROCHE«, EP-B1 211 148	576
14.15	T 1112/96, »Erythropoietin production/GENETICS INSTITUTE«, EP-B1 205 564	576
14.16	T 542/95, »TNF/YEDA«, EP-B1 186 833	576
14.17	T 1147/98, »Cartilage-inducing factor/CELTRIX PHARMACEUTICALS INC.«, EP-B1 169 016	577
14.18	T 188/97, »NANBV/Chiron Corporation«, EP-B1 318 216	578
14.19	T 479/97, »Expression system/NOVARTIS«, EP-B1 353 188	578
14.20	T 351/98, »HIV-I/CHIRON CORPORATION«, EP-B1 181 150	579
14.21	T 342/98, »A. orizae/NOVOZYME«, EP-B1 238 023	580
14.22	T 93/98, »TNF inhibiting protein/BASF«, EP-B1 471 701	580
14.23	T 1099/99, »Filamentous fungi/GENENCOR«, EP-B1 215 594	582
14.24	T 216/96, »Process for amplifying, detecting and/or cloning nucleic acid sequences/F. HOFFMANN-LA ROCHE AG«, EP-B1 200 362	582
14.25	T 785/97, »Support-bound oligonucleotides/OXFORD GENE TECHNOLOGY LIMITED«, EP-B1 386 229	583
14.26	T 280/00, »Inhibin/GENENTECH«, EP-B1 222 491	583
14.27	T 120/00, »Mycobacteria/COGENT«, EP-B1 460 041	583
14.28	T 279/00, »Asymmetric reduction process/AVECIA LTD.«, EP-B1 658 211	584
14.29	T 356/00, »Mammary gland FIX intron construct/PPL«, EP-B1 396 699	584
14.30	T 552/00, »3D-MPL/SMITHKLINE«, EP-B1 689 454	585
14.31	T 1127/00, »Ribozymes/GENE SHEARS«, EP-B1 321 201	585
14.32	T 8/01, »Chimeric chain receptors/CELL GENESYS«, EP-B1 517 895	586
14.33	T 351/01, »Tissue factor protein/GENENTECH«, EP-B1 278 776	586
14.34	T 423/01, »Length polymorphisms/MAX-PLANCK-GESELLSCHAFT«, EP-B1 438 512	587
14.35	T 486/01, »IGF-1/GENENTECH, INC.«, EP-B1 597 033	588
14.36	T 1014/01, »Recombinant immunoconjugates/BRISTOL-MYERS SQUIBB CO.«, EP-B1 439 095	588
14.37	T 1080/01, »Thermostable enzyme/F. HOFFMANN LA ROCHE«, EP-B1 258 017	589
14.38	T 1074/00, »Hematopoietic growth factors/GENETICS INSTITUTE«, EP-B1 314 705	589
14.39	T 843/03, »Human papillomavirus/THE UNIVERSITY OF ROCHESTER«, EP-A 688 227	590
14.40	T 15/01, »Mystery swine disease/SDLO«, EP-B1 587 780	590
14.41	T 20/04, »Flt3 ligands/SCHERING«, EP-B1 699 236	592
14.42	T 464/94, »Transformation of plant genetic material/NOVARTIS«, EP-B1 164 575	592
14.43	T 676/01, »Treatment of inflammation/SONORAN DESERT CHEMICALS LLC«, EP-B1 512 090	593
14.44	T 1010/01, »Acellular vaccine/MEDEVA B.V.«, EP-B1 471 726	593
14.45	T 293/04, »Lyme vaccine/BAXTER«, EP-B1 522 560	594
14.46	T 1127/03, »Wound healing/RENOVO«, EP-B1 585 242	594
14.47	T 70/05, »Apoptosis receptors/GENENTECH«, EP-A1 904 366	594
14.48	T 1399/04, »Combination therapy HCV/SCHERING«, EP-B1 956 861	595
14.49	T 562/04, »Factor VII/von Willebrand factor complex/OCTAPHARMA«, EP-B1 625 161	595

14.50	T 1190/03, »Orphan receptor/KARO BIO«, EP-B1 792 292	596
14.51	T 903/05, »Teleomerase peptides/GEMVAX«, EP-B1 1 093 381	597
14.52	T 1147/02, »Antibiotic resistance/PASTEUR«, EP-B1 639 229	598
14.53	T 1213/05, »Breast and ovarian cancer/UNIVERSITY OF UTAH«, EP-B1 705 902	598
14.54	T 250/06, »Opioid receptor genes/UNIVERSITY OF CALIFORNIA«, EP-B1 656 007	600
14.55	T 1380/05, »Protein stabilization/NOVOZYMES«, EP-B1 353 250	601
14.56	T 80/05, »Method of diagnosis/UNIVERSITY OF UTAH«, EP-B1 699 754	601
14.57	T 666/05, »Mutation/UNIVERSITY OF UTAH«, EP-B1 705 903	602
14.58	T 1127/06, »Beta-amyloid peptide/ELAN«, EP-B1 736 106	602
14.59	T 1338/06, »Microarray/LELAND STANFORD JUNIOR UNIVERSITY«, EP-B1 804 731	603
14.60	T 331/07, »Negative-strand RNA virus/CONZELMANN«, EP-B1 702 085	604
14.61	T 382/07, »Ethereic oils/D&W TRADING«, EP-B1 828 502	605
14.62	T 415/07, »Ribosomal display/DISCERNA LTD«, EP-B1 985 032	606
14.63	T 156/08, »BRCA2/UNIVERSITY OF UTAH«, EP-A1 1 260 520	606
14.64	T 1834/09, »Apo-2DcR/GENENTECH«, EP-A1 1 032 661	607
14.65	T 146/07, »Prenatal diagnosis/ISIS«, EP-B1 994 963	608
14.66	T 902/07, »BRCA2/CANCER RESEARCH TECHNOLOGY«, EP-B1 858 467	609
14.67	T 2165/08, »Bi-cyclic nucleoside analogues/EXIQON«, EP-B1 1 015 469	610
14.68	T 2226/10, »HIV-3/INNOGENETICS« (June 28, 2012), EP-B1 657 532	611
15	Novelty: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	613
15.1	Novelty: EPO (Article 54 EPC/Article 54 EPC2000)	613
15.2	Novelty: US	631
15.3	Novelty: JPO	646
16	Novelty: The EPO's Case Law	654
16.1	Decisions on Novelty for Protein Inventions	654
16.2	Decisions on Novelty for DNA Sequence Inventions	692
16.3	Decisions on Novelty of Inventions Relating to Systems for the Expression of DNA Sequences	707
16.4	Decisions on Novelty for Plasmid Inventions	722
16.5	Decisions on Novelty for Inventions on Antibody Technology	726
16.6	Decisions on Novelty for Plant and Animal Related Inventions	744
16.7	Viruses and Their Epitopes	759
16.8	PCR and Other in vitro Nucleic Acid Amplification and Detection Methods	774
16.9	Microorganisms and How to Modify Them	786
16.10	Other Decisions on Novelty	796
17	Inventive Step: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	831
17.1	Inventive Step: EPO (Article 56 EPC)	831
17.2	Inventive Step: US	845
17.3	Inventive Step: JPO	869

Table of Contents – Detailed

18	Inventive Step: The EPO's Case Law	879
18.1	Decisions on Inventive Step for Protein Inventions (Including Inventions Relating to Methods for the Preparation of Proteins and their Use)	879
18.2	Decisions on Inventive Step for Nucleic Acid (Sequence) Inventions	948
18.3	Decisions on Inventive Step of Inventions Relating to Systems for the Expression of DNA Sequences	1017
18.4	Decisions on Inventive Step for Plasmid Inventions	1048
18.5	Decisions on Inventive Step for Inventions on Antibody Technology	1051
18.6	Decisions on Inventive Step for Plant and Animal related Inventions	1093
18.7	Viruses and Their Epitopes	1127
18.8	PCR and Other in vitro Nucleic Acid Amplification and Detection Methods	1170
18.9	Microorganisms and How to Modify Them	1191
18.10	Other Decisions on Inventive Step	1213
19	Decisions of the EPO Dealing with Procedural Issues and Procedural Changes Due to EPC2000	1264
19.1	Substantive Examination: General	1264
19.2	Opposition Proceedings: Introduction of New Grounds	1279
19.3	Opposition Proceedings: The Filing of New Claim Requests	1283
19.4	Opposition Proceedings: The Filing of New Documents/Experimental and Other Evidence and the Submission of New Arguments	1304
19.5	Opposition Proceedings: Adaption of the Description	1316
19.6	Opposition Proceedings: Third Party Intervention/Third Party Observations	1316
19.7	Opposition Proceedings: Strawman	1321
19.8	Opposition Proceedings: Substantial Procedural Violation and Failures in the Opposition Division's Decision	1323
19.9	Opposition and Appeal Proceedings: Miscellaneous	1330
20	Drafting Claims for a European Patent Application	1357
21	Examples of Claims for a US Patent Application	1359
21.1	Introduction	1359
21.2	Claims Relating to Chemical Compounds	1363
21.3	Claims Relating to DNA Sequences, Vectors, Plasmids, Host Cells, and Recombinant DNA molecules	1363
21.4	Examples of Claims Relating to Polypeptides	1365
21.5	Examples of Claims Relating to Microorganisms	1366
21.6	Examples of Claims Relating to Monoclonal Antibodies	1366
21.7	Examples of Claims Relating to Transgenic Plants and Animals	1367
21.8	Method of Treatment Claims	1369
21.9	Claims That Are Not Allowable In The U.S.	1372
22	Examples of Claims for a Japanese Patent Application	1373
22.1	Introduction	1373
22.2	Claims Relating to Chemical Compounds	1375
22.3	Claims Relating to DNA Sequences	1375
22.4	Claims Relating to Recombinant Proteins	1376
22.5	Claims Relating to Vectors and Transformants	1377
22.6	Claims Relating to Microorganisms	1378

22.7	Claims Relating to Monoclonal Antibodies	1378
22.8	Claims Relating to Transgenic Plants	1379
22.9	Claims Relating to Transgenic Animals	1379
22.10	Claims Relating to Screening Methods	1379
22.11	Claims Relating to Antagonists/Inhibitors or Agonists	1380
22.12	Claims Relating to Pharmaceutical Inventions	1380
22.13	Claims Relating to iPS	1382
23	How to Draft and File a European Patent Application	1383
23.1	The Title of the Invention	1383
23.2	The Indication of the Field of the Invention	1383
23.3	The Acknowledgment of the Prior Art	1383
23.4	The Technical Problem Underlying the Invention	1383
23.5	The Solution	1384
23.6	The Legends to the Figures	1386
23.7	Examples	1386
23.8	Sequence Listings	1387
23.9	The Abstract	1388
23.10	ONLINE FILING (OLF) and New Online Filing under EPO's Case Management Systems (CMS)	1388
23.11	Unity of Invention and Divisional Applications	1389
23.12	Further Formal Issues and Changes due to EPC2000 that have to be considered when Drafting Patent Applications	1392
24	How to Draft the Description of a US Patent Application	1395
24.1	The Elements of a U.S. Patent Application	1395
24.2	Meeting the Requirements of 35 U.S.C. § 112, first paragraph	1401
25	How to Draft the Description of a Japanese Patent Application	1417
25.1	Elements of a Japanese Patent Application	1417
25.2	Title of the Invention	1417
25.3	Technical Field	1417
25.4	Prior Art	1417
25.5	Problems to be Solved by the Invention	1418
25.6	Means for Solving the Problems	1418
25.7	Effects of the Invention	1418
25.8	Mode for Carrying out the Invention	1419
25.9	Examples	1421
25.10	Sequence Listing	1422
25.11	Abstract	1422
26	How to Keep Notebooks for Successful Interferences	1423
26.1	Record Keeping To Establish Dates Of Invention	1423
26.2	Notebooks	1425
26.3	Electronic And Other Records Of Experiments	1427

Table of Contents – Detailed

27 Extensions to Patent Term 1428

27.1 Supplementary Protection Certificates (SPCs) for Pharmaceuticals and Plant
Protection Products in Europe 1428

27.2 Extensions to Patent Term in the US 1430

27.3 Patent Term Extensions: JPO 1435

28 AIA Post-Grant Proceedings in the United States 1438

28.1 Introduction 1438

28.2 Covered Business Method Review 1441

28.3 Inter Partes Reviews 1443

28.4 Post-Grant Review 1445

28.5 Timeline and Process of Post-Grant Reviews 1446

28.6 Illustrative Bio/Pharma Post-Grant Proceedings 1455

Decisions of the EPO 1459

Decisions on U.S. Cases 1503

Decisions on Japanese Cases 1526

European Statutes 1529

Cross-Reference List Article EPC1973 Article/Rule EPC2000 1530

Cross-Reference List Rule EPC1973 Rule EPC2000 1532

U.S. Statutes 1537

Japanese Statutes 1538

Index 1539